oluntary Scheme for Branded Medicine Pricing
CSL Seqirus announces strengthened vaccine partnership with UK government
The partnership introduces a world-first flu vaccine and extends the health security pandemic agreement
New benchmark reveals significant digital maturity gap across UK POM companies’ product-information estates
A new benchmark maps 100 UK prescription medicine companies across five maturity bands and finds a market at very different stages of digital development
Why patient-centricity depends on site-centricity in clinical trials
Explore why patient-centricity in clinical trials relies on site-centricity, emphasising the need to design trials that empower site teams to better support patients.
Why pharma website projects stall long before compliance becomes the problem
Pharma teams often blame compliance when digital projects slow down. In reality, the bigger issue is usually weaker ownership, unclear review models and content structures that were never designed for...
Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030
[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...
Streamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...
Current CGT landscape and future outlook
What makes CGT unique Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...
Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals
This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...
Navigating the complexities of launch preparation for Cell and Gene Therapy
Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...
NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine
More than 11,000 people are diagnosed with head and neck cancers every year in England
Navigating NHS Market Access: Policy Change and Opportunity in England
With the changes at NHS England and the publishing of the 10-Year Plan, there is a lot of talk of change in the NHS in England. But what do these...
Digital Transformation in the NHS’s 10-Year Plan: Techno-Optimism and the Limits of Efficiency
Here, Evelyne Priestman (Senior Consultant – HEOR) and Mary Baker (Senior Medical Writer) at Petauri Evidence explore the National Health Service (NHS) in England’s newly unveiled 10-year plan through the...